Shire PLC (SHPG) Shares Sold by Shelton Capital Management
Shelton Capital Management lowered its stake in Shire PLC (NASDAQ:SHPG) by 2.9% in the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 21,615 shares of the biopharmaceutical company’s stock after selling 655 shares during the period. Shelton Capital Management’s holdings in Shire PLC were worth $3,572,000 at the end of the most recent quarter.
Several other institutional investors also recently modified their holdings of the stock. Vanguard Group Inc. raised its position in Shire PLC by 0.9% in the 1st quarter. Vanguard Group Inc. now owns 1,542,634 shares of the biopharmaceutical company’s stock worth $268,773,000 after purchasing an additional 13,665 shares during the last quarter. Ameriprise Financial Inc. lifted its holdings in Shire PLC by 14.7% during the 2nd quarter. Ameriprise Financial Inc. now owns 1,510,227 shares of the biopharmaceutical company’s stock worth $249,577,000 after buying an additional 194,059 shares in the last quarter. BlackRock Inc. lifted its holdings in Shire PLC by 4,217.7% during the 1st quarter. BlackRock Inc. now owns 1,433,475 shares of the biopharmaceutical company’s stock worth $249,755,000 after buying an additional 1,400,275 shares in the last quarter. Janus Capital Management LLC lifted its holdings in Shire PLC by 10.7% during the 1st quarter. Janus Capital Management LLC now owns 1,365,226 shares of the biopharmaceutical company’s stock worth $237,854,000 after buying an additional 132,446 shares in the last quarter. Finally, Bank of America Corp DE boosted its position in Shire PLC by 19.7% in the 1st quarter. Bank of America Corp DE now owns 1,326,114 shares of the biopharmaceutical company’s stock valued at $231,049,000 after buying an additional 218,291 shares during the last quarter. 19.28% of the stock is owned by institutional investors and hedge funds.
A number of analysts have commented on SHPG shares. Cantor Fitzgerald set a $222.00 target price on shares of Shire PLC and gave the stock a “buy” rating in a report on Saturday, July 1st. Stifel Nicolaus cut their price target on Shire PLC from $250.00 to $245.00 and set a “buy” rating on the stock in a research note on Friday, June 9th. Jefferies Group LLC reissued a “buy” rating and issued a $216.00 price target (down previously from $239.00) on shares of Shire PLC in a research note on Friday, June 9th. Royal Bank Of Canada set a $218.00 price target on Shire PLC and gave the stock a “buy” rating in a research report on Thursday, June 8th. Finally, ValuEngine raised Shire PLC from a “hold” rating to a “buy” rating in a research note on Thursday, July 6th. One investment analyst has rated the stock with a sell rating, ten have given a hold rating and fourteen have given a buy rating to the company. Shire PLC currently has an average rating of “Buy” and a consensus target price of $220.08.
Shares of Shire PLC (SHPG) traded up 1.12% during midday trading on Wednesday, reaching $154.86. The company had a trading volume of 275,643 shares. Shire PLC has a 12-month low of $139.36 and a 12-month high of $198.58.
Shire PLC (NASDAQ:SHPG) last posted its quarterly earnings results on Friday, October 27th. The biopharmaceutical company reported $3.37 earnings per share for the quarter, missing the consensus estimate of $3.66 by ($0.29). Shire PLC had a net margin of 4.70% and a return on equity of 14.10%. Equities research analysts anticipate that Shire PLC will post $14.93 earnings per share for the current year.
The business also recently disclosed a semiannual dividend, which will be paid on Friday, October 20th. Stockholders of record on Friday, September 8th will be given a dividend of $0.1527 per share. The ex-dividend date is Thursday, September 7th. This represents a dividend yield of 0.21%. Shire PLC’s dividend payout ratio (DPR) is presently 41.07%.
Shire PLC Company Profile
Shire plc is a biotech company focused on serving people with rare diseases and other specialized conditions. The Company’s segment is engaged in research, development, licensing, manufacturing, marketing, distribution and sale of specialist medicines. It focuses its development resources on projects in various therapeutic areas (TAs), including Neuroscience, Ophthalmology, Hematology, Oncology, Immunology, Gastrointestinal (GI)/Metabolic/Endocrinology Diseases.
Want to see what other hedge funds are holding SHPG? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Shire PLC (NASDAQ:SHPG).
Receive News & Stock Ratings for Shire PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Shire PLC and related stocks with our FREE daily email newsletter.